arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Liquidia Corp

LQDA
$44.49 ▼ -2.90 (-6.12%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
8 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Liquidia Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.8B
Dividend Yield —
Revenue Growth 1031.2% ↗
Op. Margin -32.5%
ROIC -90.7% ↗
FCF / Share $-0.47 ↗
Trailing P/E —
Price / Book 86.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$158.32M
↑ +1031.2% —
Net Income Profit after all expenses
$-68.92M
↑ +46.3% —
Operating Margin Operating profit as % of sales
-32.5%
↑ +92.3% 7th
FCF / Share Free cash flow per share
$-0.47
↑ +62.8% —
Long-Term Debt Long-term obligations
$19.88M
↑ +91.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
7
Returns ↓
4
Cash Quality ↓
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 28 quarters